The Long and Short of It: New Lessons on the Optimal Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer and Where We Need to Go From Here

Recently in the International Journal of Radiation Oncology, Biology, Physics, we have seen 3 articles providing updates or reanalyses from landmark trials testing the optimal duration of androgen deprivation therapy (ADT) with radiation in high-risk prostate cancer. Although it was started more than 25 years ago by Dr Gerald Hanks, the pioneering radiation oncology leader and former American Society for Radiation Oncology president who sadly passed away on December 20, 2017, the Radiation Therapy Oncology Group (RTOG) protocol 92-02 continues to provide valuable insights through its updates, as does the more recent DART 01/05 trial, and I will highlight them both in this month's Oncology Scan.

https://ift.tt/2NBfmcp